1. Home
  2. RFIL vs MDWD Comparison

RFIL vs MDWD Comparison

Compare RFIL & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RF Industries Ltd.

RFIL

RF Industries Ltd.

HOLD

Current Price

$17.54

Market Cap

183.3M

Sector

Technology

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.96

Market Cap

212.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFIL
MDWD
Founded
1979
2000
Country
United States
Israel
Employees
289
N/A
Industry
Electrical Products
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.3M
212.1M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
RFIL
MDWD
Price
$17.54
$16.96
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$11.25
$36.00
AVG Volume (30 Days)
209.5K
51.4K
Earning Date
06-15-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
N/A
EPS
N/A
N/A
Revenue
$55,325,000.00
N/A
Revenue This Year
$9.65
$48.92
Revenue Next Year
$6.40
$35.04
P/E Ratio
$1,203.00
N/A
Revenue Growth
10.22
N/A
52 Week Low
$3.98
$14.90
52 Week High
$19.00
$22.51

Technical Indicators

Market Signals
Indicator
RFIL
MDWD
Relative Strength Index (RSI) 64.53 52.24
Support Level $6.28 $16.26
Resistance Level $19.00 $18.38
Average True Range (ATR) 1.35 0.52
MACD 0.06 0.02
Stochastic Oscillator 75.76 59.23

Price Performance

Historical Comparison
RFIL
MDWD

About RFIL RF Industries Ltd.

RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: